US OptionsDetailed Quotes
OCGN240816P2500
- 0.86
- -0.09-9.47%
15min DelayClose Jul 24 16:00 ET
0.86High0.86Low
0.86Open0.95Pre Close1 Volume11 Open Interest2.50Strike Price86.00Turnover135.97%IV-2.50%PremiumAug 16, 2024Expiry Date0.90Intrinsic Value100Multiplier23DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8723Delta0.4003Gamma1.73Leverage Ratio-0.0022Theta-0.0010Rho-1.51Eff Leverage0.0008Vega
Ocugen Stock Discussion
Sign in to post a comment
$Ocugen(OCGN.US$ i regret not buying this share
1
$Ocugen(OCGN.US$ yes slow and steady
1
1
$Ocugen(OCGN.US$ slow and steady
$Ocugen(OCGN.US$ Reuters· just
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in Gardian Study for Stargardt Disease
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in Gardian Study for Stargardt Disease
$Ocugen (OCGN.US)$ it squeezed at this time last year so you might as well jump in a month before earnings if that's where you're minds at
$Ocugen(OCGN.US$ You guys that are holding still good? Will enter back before they announce their next quarter earnings ![]()
3
11
$Ocugen(OCGN.US$ Mississippi Retina Associates: Revolutionizing Retinal Care
Businesswire·
Mississippi's Pioneering Journey into Gene Therapy
MADISON, Miss.--(BUSINESS WIRE)--#innovation--Mississippi Retina Associates' very own Retina Research Institute of Mississippi, proudly announces a groundbreaking milestone in Mississippi medical history: the successful completion of the first-ever retina-specific gene therapy surgery in the state. Spearheaded by ou...
Businesswire·
Mississippi's Pioneering Journey into Gene Therapy
MADISON, Miss.--(BUSINESS WIRE)--#innovation--Mississippi Retina Associates' very own Retina Research Institute of Mississippi, proudly announces a groundbreaking milestone in Mississippi medical history: the successful completion of the first-ever retina-specific gene therapy surgery in the state. Spearheaded by ou...
3
4
$Ocugen(OCGN.US$ what happen ?
$Ocugen(OCGN.US$ Ocugen Inc -Dsmb Recommends Continuing With High-Dose Cohort Dosing With Concurrent Phase 2 Dosing
No comment yet
103045055 : why ? what did you see from this share ? just curious